Preview Mode Links will not work in preview mode

Innovate Fort Worth

Apr 26, 2022

Abexxa Biologics is changing how we treat cancer. Using immunotherapy, Jon Weidanz is treating cancer through novel biotechnology that targets cancer cells and boosts immune systems of patients. Jon and Debra Weidanz are the co-founders of the biotech company Abexxa Biologics, that was acquired by Boehringer Ingelheim (BI) in 2021. Jon shares how he raised capital from BI venture funds, how Abexxa won their “golden ticket” competition and how they went from lab discovery to acquisition in just a few years.